for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.A

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.92

 - 

6.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.47
Open
--
Volume
--
3M AVG Volume
0.00
Today's High
--
Today's Low
--
52 Week High
6.92
52 Week Low
6.92
Shares Out (MIL)
98.92
Market Cap (MIL)
640.00
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Sinovac Biotech Q3 Non-GAAP Earnings Per Share $0.07

Sinovac Biotech Q2 Earnings Per Share $0.11

Sinovac Q1 NON-GAAP Earnings Per Share $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sinovac Biotech Ltd.

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Industry

Biotechnology & Drugs

Contact Info

39 Shangdi Xi Road, Haidian District

+86.10.82890088

http://www.sinovac.com/

Executive Leadership

WeiDong Yin

Chairman of the Board, President, Chief Executive Officer, Secretary

Nan Wang

Chief Financial Officer, Vice President

Xiaomei Yin

Vice President - Sales and Marketing

Qiang Gao

Vice President - Research and Development

Jing Li

Vice President - Quality and Production

Key Stats

Price To Earnings (TTM)
37.71
Price To Sales (TTM)
2.93
Price To Book (MRQ)
2.40
Price To Cash Flow (TTM)
18.90
Total Debt To Equity (MRQ)
1.41
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Sinovac Biotech activates 'poison pill' defense in rare move

Sinovac Biotech Ltd, a Nasdaq-listed Chinese vaccine developer, activated a shareholders rights plan on Friday, according to a press release seen by Reuters, the first time a company has used a "poison pill" takeover defense in more than a decade.

BRIEF-Sinovac Amends Shareholder Rights Plan

* SINOVAC BIOTECH LTD - AMENDMENT EXTENDS EXPIRATION OF SHAREHOLDER RIGHTS PLAN FROM MARCH 27 TO MARCH 27, 2019 Source text for Eikon: Further company coverage:

BRIEF-Sinovac Provides Update On Going Private Transaction

* SINOVAC BIOTECH - EXPECTS TO FILE AMENDED GOING-PRIVATE STATEMENT, INCLUDING A DEFINITIVE PROXY STATEMENT AS AN EXHIBIT, WITH U.S. SEC IN DUE COURSE Source text for Eikon: Further company coverage:

BRIEF-Sinovac Biotech Receives Positive Decision On Hepatitis A Vaccine From WHO

* SINOVAC BIOTECH RECEIVES POSITIVE DECISION ON ITS HEPATITIS A VACCINE FROM WORLD HEALTH ORGANIZATION

BRIEF-Sinovac Biotech Announces Update On Nasdaq Matters

* SINOVAC BIOTECH- NASDAQ HEARINGS PANEL GRANTED REQUEST TO EXTEND STAY OF SUSPENSION IN TRADING OF CO'S COMMON SHARES PENDING HEARING ON JAN 11, 2018 Source text for Eikon: Further company coverage:

BRIEF-Sinovac reports Q4 earnings per share $0.08

* Sinovac files 2016 annual report on form 20-F and reports unaudited fourth quarter 2016 financial results

BRIEF-Sinovac Biotech receives delisting determination letter from Nasdaq

* Sinovac Biotech announces receipt of delisting determination letter from Nasdaq Source text for Eikon: Further company coverage:

BRIEF-Sinobioway Consortium provides update on acquiring Sinovac Biotech at $8 per share

* Sinobioway Consortium provides update on acquiring Sinovac Biotech (Nasdaq: SVA) at the purchase price of $8 per share

BRIEF-Sinovac Biotech preliminary phase III data shows Varicella vaccine was 87.1 pct efficacious against Chickenpox ​

* Sinovac reports preliminary top-line results from phase III clinical trial for Varicella vaccine candidate against Chickenpox

BRIEF-Sinovac Biotech announces certain updates relating to delayed filing of annual report on form 20-F

* Sinovac Biotech announces certain updates relating to delayed filing of annual report on form 20-F

BRIEF-Sinobioway consortium provides update on Sinovac Biotech acquisition

* Sinobioway consortium provides update on acquiring Sinovac Biotech at the purchase price of $8 per share

BRIEF-Shandong Sinobioway's consortium makes an offer to take Sinovac Biotech private

* Says its consortium offers to buy Sinovac Biotech Ltd at $8 per share to take it private

BRIEF-Sinovac Biotech enters into agreement for going-private transaction

* Sinovac Biotech Ltd enters into definitive agreement for going-private transaction

BRIEF-Sinovac Biotech announced it is delaying its annual report on form 20-F

* Announced it is delaying its annual report on form 20-F for the year ended December 31, 2016 - SEC filing

BRIEF-Sinovac amends shareholder rights plan

* Sinovac Biotech Ltd - amendment extends expiration date of plan from March 27, 2017 to March 27, 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up